|
font size Sign in
The U.S. Food and Drug Administration’s performance in its review of new drug applications varies widely depending on the therapeutic area involved, according to a new report from the California Healthcare Institute and the Boston Consulting Group. The report suggests that the agency could learn from areas in which it is high performing to improve its approach in others. We spoke to David Gollaher, CEO of the California Healthcare Institute, about the report, why the numbers used to track FDA performance may provide an incomplete picture, and the need for new measures of success. Read More ![]()
Deals
Regulatory
Healthcare Economics
Patents
Drug Development
HIV/AIDS
Trials and Tribulations
Business Strategy
![]()
Now Available
The Burrill Report May 2012
Podcast
Protalix Approval a Win for Its Manufacturing Technology
Burrill Report Data Center
Finance Scorecard
By the numbers
Daiichi Sankyo Enters Biosimilars Arena with Coherus BioSciences
|